86347-14-0 Usage
Adverse Reactions
As with all α2-agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists. Incidents of prolonged sedation, bradycardia, cyanosis, vomiting, apnea, death from circulatory failure with severe congestion of lungs, liver, kidney and recurrence of sedation after initial recovery have been reported.
Description
Medetomidine is a synthetic compound used as a surgical anesthetic and analgesic. It is normally found as its hydrochloride salt, medetomidine hydrochloride. Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma. In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. The marketed product is a racemic mixture of two stereoisomers from which dexmedetomidine is the main active isomer.
Uses
Different sources of media describe the Uses of 86347-14-0 differently. You can refer to the following data:
1. Analgesic
(veterinary); sedative (veterinary).
2. Medetomidine is used in method for synthesizing Medetomidine using 2,3-Dimethylphenylmagnesium Bromide.
Indications
Medetomidine Hydrochloride is indicated for use as a sedative and analgesic in dogs over 12 weeks of age to facilitate clinical examinations, clinical procedures, minor surgical procedures not requiring muscle relaxation, and minor dental procedures where intubation is not required. The IV route of administration is more efficacious for dental care.
Clinical Use
Medetomidine is a potent non-narcotic α2-adrenoreceptor agonist which produces sedation and analgesia. These effects are dose dependent in depth and duration. Profound sedation and recumbency, with reduced sensitivity to environmental stimuli (sounds, etc.), are seen with medetomidine.
Side effects
Bradycardia with occasional atrioventricular blocks will occur together with decreased respiratory rates. Body temperature is slightly or moderately decreased. Urination typically occurs during recovery at about 90 to 120 minutes posttreatment. In approximately 10% of treated dogs, occasional episodes of vomiting occur between 5 to 15 minutes posttreatment. An increase in blood glucose concentration is seen due to α2-adrenoreceptor-mediated inhibition of insulin secretion.
Veterinary Drugs and Treatments
Medetomidine is labeled for use as a sedative and analgesic in dogs
over 12 weeks of age to facilitate clinical examinations and procedures,
minor surgical procedures not requiring muscle relaxation,
and minor dental procedures not requiring intubation. The manufacturer
recommends the IV route of administration for dental
procedures.
Medetomidine has also been used in cats, primarily in Europe.
But there is apparently much less data available to evaluate its use;
caution is advised.
Precautions
In extremely nervous or excited dogs, levels of endogenous catecholamines are high due to the animal’s state of agitation. The pharmacological response elicited by α2-agonists (e.g., medetomidine) in such animals is often reduced, with depth and duration of sedative/analgesic effects ranging from slightly diminished to nonexistent. Highly agitated dogs should therefore be put at ease and allowed to rest quietly prior to receiving Medetomidine Hydrochloride. Allowing dogs to rest quietly for 10 to 15 minutes after injection may improve the response to Medetomidine Hydrochloride. In dogs not responding satisfactorily to treatment with Medetomidine Hydrochloride, repeat dosing is not recommended.
Check Digit Verification of cas no
The CAS Registry Mumber 86347-14-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,3,4 and 7 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 86347-14:
(7*8)+(6*6)+(5*3)+(4*4)+(3*7)+(2*1)+(1*4)=150
150 % 10 = 0
So 86347-14-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)
86347-14-0Relevant articles and documents
Novel method for the preparation of Medetomidine
-
, (2021/02/09)
The present invention relates to a method for manufacturing medetomidine from 1H-imidazole-4-carbaldehyde and 1-bromo-2,3-dimethylbenzene. The present invention provides a novel method for manufacturing medetomidine represented by chemical formula I. The method for manufacturing medetomidine according to the present invention has an effect of having stability of a manufacturing process and being able to manufacture a final material with high purity.
Synthetic process of dexmedetomidine hydrochloride
-
Paragraph 0004; 0016-0019, (2020/08/27)
The present invention provides a dexmedetomidine hydrochloride synthesis process, and relates to the technical field of drug synthesis, the dexmedetomidine hydrochloride synthesis process uses 1-(1-chloroethyl)-2,3-xylene and trimethylsilylimidazole as starting materials, and alkylation, resolution, dissociation and salification reactions are performed to synthesize the dexmedetomidine hydrochloride. According to the method, L-tartaric acid is used as a resolving agent, and the resolving efficiency is improved by controlling the proportion of the resolving agent and the number of resolving times; a one-step method is adopted for free salification, intermediate quality control and purification steps are not needed, the purity of the prepared finished product is larger than 99.8%, the isomeris not larger than 0.2%, through process optimization, the efficiency of the synthesis process is remarkably improved, and the obtained finished product directly meets the commercial production requirements of raw material medicines.
Method for synthesizing dexmedetomidine hydrochloride
-
, (2019/04/26)
The invention belongs to the technical field of drug preparation, and particularly relates to a method for synthesizing dexmedetomidine hydrochloride. The method for synthesizing dexmedetomidine hydrochloride comprises the steps that reaction of 2,3-dimethylbenzoyl chloride and 1-N,N-dimethyl sulfonyl-2-(tert-butyldimethylsily)-5-(2,3-dimethyl benzoyl) imidazole is adopted, reflux is carried out to remove a protecting group under the action of hydrochloric acid, intermediate 4(5)-(2,3-dimethyl benzoyl) imidazole is obtained, lastly, reduction is carried out to obtain medetomidine under the action of monomethylamine, dexmedetomidine is obtained through the resolution of medetomidine under the action of tartaric acid, and lastly, dexmedetomidine is salified with hydrochloric acid to obtain dexmedetomidine hydrochloride. Compared with the prior art, the method for synthesizing dexmedetomidine hydrochloride has the advantages that a synthetic route is shorter, the operation is easy, and astarting material is easy to obtain.
